Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2000

Open Access 01-04-2000 | Review

Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma?

Authors: Yassine Amrani, Hang Chen, Reynold A Panettieri Jr

Published in: Respiratory Research | Issue 1/2000

Login to get access

Abstract

The cellular and molecular mechanisms that are involved in airway hyper-responsiveness are unclear. Current studies suggest that tumor necrosis factor (TNF)-α, a cytokine that is produced in considerable quantities in asthmatic airways, may potentially be involved in the development of bronchial hyper-responsiveness by directly altering the contractile properties of the airway smooth muscle (ASM). The underlying mechanisms are not known, but growing evidence now suggests that most of the biologic effects of TNF-α on ASM are mediated by the p55 receptor or tumor necrosis factor receptor (TNFR)1. In addition, activation of TNFR1 coupled to the tumor necrosis factor receptor-associated factor (TRAF)2-nuclear factor-κB (NF-κB) pathway alters calcium homeostasis in ASM, which appears to be a new potential mechanism underlying ASM hyper-responsiveness.
Literature
1.
Panettieri RA Jr, Murray RK, DePalo LR, Yadvish PA, Kotlikoff MI: A human airway smooth muscle cell line that retains physiological responsiveness. Am J Physiol (Cell Physiol) 1989, 256/25:C329-C335.
2.
Johnson SR, Knox AJ: Synthetic functions of airway smooth muscle in asthma. Trends Pharmacol Sci 1997, 18:288–292.CrossRefPubMed
3.
4.
Bouchelouche PN, Bendtzen K, Bak S, Nielsen OH: Recombinant human tumour necrosis factor increases cytosolic free calcium in murine fibroblasts and stimulates inositol-phosphate formation in L-M and arachidonic acid release in 3T3 cells. Cell Signal 1990, 2:479–487.CrossRefPubMed
5.
Corkey BE, Geschwind JF, Deeney JT, Hale DE, Douglas SD, Kilpatrick L: Ca 2+ responses to interleukin-1 and tumor necrosis factor in cultured human skin fibroblasts. Possible implications for Reye syndrome. J Clin Invest 1991, 87:778–786.CrossRefPubMedPubMedCentral
6.
Koller H, Thiem K, Siebler M: Tumour necrosis factor-alpha increases intracellular Ca 2+ and induces a depolarization in cultured astroglial cells. Brain 1996, 119:2021–2027.CrossRefPubMed
7.
Peiretti F, Fossat C, Anfosso F, Alessi MC, Henry M, Juhan-Vague I, Nalbone G: Increase in cytosolic calcium upregulates the synthesis of type I plasminogen activator inhibitor in the human histiocytic cell line U937. Blood 1996, 87:162–173.PubMed
8.
Schumann MA, Gardner P, Raffin TA: Recombinant tumor necrosis factor alpha induces calcium oscillation and calcium-activated chloride current in human neutrophils. The role of calcium/calmodulin-dependent protein kinase. J Biol Chem 1993, 268:2134–2140.PubMed
9.
Beyaert R, Heyninck K, De Valck D, Boeykens F, Van Roy F, Fiers W: Enhancement of tumor necrosis factor cytotoxicity by lithium chloride is associated with increased inositol phosphate accumulation. J Immunol 1993, 151:291–300.PubMed
10.
Rapuano BE, Bockman RS: Protein kinases A and C positively regulate G protein-dependent activation of phosphatidylinositol-specific phospholipase C by tumor necrosis factor-alpha in MC3T3 E1 osteoblasts. J Cell Biochem 1997, 65:198–208.CrossRefPubMed
11.
Wilkinson MF, Earle ML, Triggle CR, Barnes S: Interleukin-1β, tumor necrosis factor-α and LPS enhance calcium channel current in isolated vascular smooth muscle cells of rat tail artery. FASEB J 1996, 10:785–796.PubMed
12.
Cheng B, Christakos S, Mattson MP: Tumor necrosis factors protect against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994, 12:139–153.CrossRefPubMed
13.
Garcia G, Arias-Diaz J, Balibrea JL, Vara E: Modifications in calcium uptake may contribute to the effects of tumor necrosis factor on fetal islets. Transplant Proc 1994, 26:3496–3498.PubMed
14.
Krown KA, Yasui K, Brooker MJ, Dubin AE, Nguyen C, Harris GL, McDonough PM, Glembotski CC, Palade PT, Sabbadini RA: TNF alpha receptor expression in rat cardiac myocytes: TNF alpha inhibition of L-type Ca 2+ current and Ca 2+ transients. FEBS Lett 1995, 376:24–30.CrossRefPubMed
15.
Renzetti LM, Paciorek PM, Tannu SA, Rinaldi NC, Tocker JE, Wasser man MA, Gater PR: Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exptl Ther 1996, 278:847–853.
16.
Amrani Y, Martinet N, Bronner C: Potentiation by tumour necrosis factor-α of calcium signals induced by bradykinin and carbachol in human tracheal smooth muscle cells. Br J Pharmacol 1995, 114:4–5.CrossRefPubMedPubMedCentral
17.
Amrani Y, Panettieri RA Jr, Frossard N, Bronner C: Activation of the TNFα-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am J Respir Cell Mol Biol 1996, 15:55–63.CrossRefPubMed
18.
Amrani Y, Krymskaya V, Maki C, Panettieri RA Jr: Mechanisms underlying TNFa effects on agonist-mediated calcium homeostasis in human airway smooth muscle cells. Am J Physiol (Lung Cell Mol Physiol) 1997, 273/17:L1020-L1028.
19.
Hotta K, Emala CW, Hirshman CA: TNF-a upregulates G i a and G q a protein expression and function in human airway smooth muscle cells. Am J Physiol (Lung Cell Mol Physiol) 1999, 276/20:L405-L411.
20.
Nakatani Y, Nishimura Y, Nishiumua T, Maeda H, Yokoyama M: Tumor necrosis factor-a augments contraction and cytosolic Ca 2+ through phospholipase A2 in bovine tracheal smooth muscle. Eur J Pharmacol 2000, 392:175–182.CrossRefPubMed
21.
Parris JRM, Cobban HJ, Littlejohn AF, MacEwan DJ, Nixon GF: Tumor necrosis factor-α activates a calcium sensitization pathway in guinea-pig bronchial smooth muscle. J Physiol (Lond) 1999, 518:561–569.CrossRef
22.
23.
Amrani Y, Lazaar AL, Hoffman R, Amin K, Ousmer S, Panettieri RA Jr: Activation of the p55 TNFR1 coupled to TRAF2 stimulates ICAM-1 expression by modulating a thapsigargin-sensitive pathway in human tracheal smooth muscle cells. Mol Pharmacol 2000, 58:237–245.PubMed
24.
Hsu H, Xiong J, Goeddel DV: The TNF receptor-1 associated protein TRADD signals cell death and NF-κB activation. Cell 1995, 81:495–504.CrossRefPubMed
25.
Hsu H, Shu SB, Pan MG, Baichwal V, Goeddel DV: TRADD-TRAF-2 and TRAD-FADD interactions define two distinct TNF receptor-1 signal transduction pathways. Cell 1996, 84:299–308.CrossRefPubMed
26.
Amrani Y, Lazaar AL, Panettieri RA Jr: Up-regulation of ICAM-1 by cytokines in human tracheal smooth muscle cells involves an NF-κB-dependent signaling pathway that is only partially sensitive to dexamethasone. J Immunol 1999, 163:2128–2134.PubMed
27.
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995, 270:286–290.CrossRefPubMed
28.
Thastrup O: Role of Ca 2+ -ATPases in regulation of cellular Ca 2+ signalling, as studied with the selective microsomal Ca 2+ -ATPase inhibitor, thapsigargin. Agents Actions 1990, 29:8–15.CrossRefPubMed
29.
Amrani Y, Magnier C, Wuytack F, Enouf J, Bronner C: Ca 2+ increase and Ca 2+ influx in human tracheal smooth muscle cells: role of Ca 2+ pools controlled by sarco-endoplasmic reticulum Ca 2+ -ATPase 2 isoforms. Br J Pharmacol 1995, 115:1204–1210.CrossRefPubMedPubMedCentral
30.
Reilly BA, Brostrom MA, Brostrom CO: Regulation of protein synthesis in ventricular myocytes by vasopressin. J Biol Chem 1998, 273:3747–3755.CrossRefPubMed
31.
Aktas H, Fluckiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA: Depletion of intracellular Ca 2+ stores, phosphorylation of eIF2a, and sustained inhibition of translation initiation mediate the anti-cancer effects of clotrimazole. Proc Natl Acad Sci USA 1998, 95:8280–8285.CrossRefPubMedPubMedCentral
32.
Pahl HL, Baeuerle PA: The ER-overload response: activation of NF-κB. Trends Biochem Sci 1997, 22:63–67.CrossRefPubMed
33.
Adebanjo OA, Anandatheerthavarada HK, Koval AP, Moonga BS, Biswas G, Sun L, Sodam BR, Bevis PJ, Huang CL, Epstein S, Lai FA, Avadhani NG, Zaidi M: A new function for CD38/ADP ribosyl cyclase in nuclear Ca 2+ homeostasis. Nature Cell Biol 1999, 1:409–414.CrossRefPubMed
Metadata
Title
Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma?
Authors
Yassine Amrani
Hang Chen
Reynold A Panettieri Jr
Publication date
01-04-2000
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2000
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/rr12

Other articles of this Issue 1/2000

Respiratory Research 1/2000 Go to the issue

Commentary

The gene encoding interleukin-13: a susceptibility locus for asthma and related traits

Commentary

Size does matter: overcoming the adeno-associated virus packaging limit

Commentary

Immune modulation in the treatment of respiratory infection

Review

Hypoxic pulmonary vasoconstriction: role of voltage-gated potassium channels

Review

From fruitflies to mammals: mechanisms of signalling via the Sonic hedgehog pathway in lung development

Commentary

Interleukin-4 receptor alpha gene variants and allergic disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits